CoChat
Sign Up
Cited by 16

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

The effects of enhancing angiotensin converting enzyme in myelomonocytes on ameliorating Alzheimer’s-related disease and preserving cognition

Danziger, Ron, Fuchs, Dieu-Trang, Koronyo, Yosef, Rentsendorj, Altan, Sheyn, Julia, Hayden, Eric Y., Teplow, David B., Black, Keith L., Fuchs, Sebastien, Bernstein, Kenneth E., Koronyo-Hamaoui, Maya·2023·Frontiers in Physiology
DOI 10.3389/fphys.2023.1179315PMC PMC10326285
Open this paper in CoChat — free account

Abstract

This review examines the role of angiotensin-converting enzyme (ACE) in the context of Alzheimer’s disease (AD) and its potential therapeutic value. ACE is known to degrade the neurotoxic 42-residue long alloform of amyloid β-protein (Aβ 42), a peptide strongly associated with AD. Previous studies in mice, demonstrated that targeted overexpression of ACE in CD115+ myelomonocytic cells (ACE10 models) improved their immune responses to effectively reduce viral and bacterial infection, tumor growth, and atherosclerotic plaque. We further demonstrated that introducing ACE10 myelomonocytes (microglia and peripheral monocytes) into the double transgenic APP SWE/PS1 ΔE9 murine model of AD (AD+ mice), diminished neuropathology and enhanced the cognitive functions. These beneficial effects were dependent on ACE catalytic activity and vanished when ACE was pharmacologically blocked. Moreover, we revealed that the therapeutic effects in AD+ mice can be achieved by enhancing ACE expression in bone marrow (BM)-derived CD115+ monocytes alone, without targeting central nervous system (CNS) resident microglia. Following blood enrichment with CD115+ ACE10-monocytes versus wild-type (WT) monocytes, AD+ mice had reduced cerebral vascular and parenchymal Aβ burden, limited microgliosis and astrogliosis, as well as improved synaptic and cognitive preservation. CD115+ ACE10-versus WT-monocyte-derived macrophages (Mo/MΦ) were recruited in higher numbers to the brains of AD+ mice, homing to Aβ plaque lesions and exhibiting a highly Aβ-phagocytic and anti-inflammatory phenotype (reduced TNFα/iNOS and increased MMP-9/IGF-1). Moreover, BM-derived ACE10-Mo/MΦ cultures had enhanced capability to phagocytose Aβ 42 fibrils, prion-rod-like, and soluble oligomeric forms that was associated with elongated cell morphology and expression of surface scavenger receptors (i.e., CD36, Scara-1). This review explores the emerging evidence behind the role of ACE in AD, the neuroprotective properties of monocytes overexpressing ACE and the therapeutic potential for exploiting this natural mechanism for ameliorating AD pathogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphys.2023.1179315

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Neuroprotection by ACE-overexpressing monocytes and macrophages in APPSWE/PS1ΔE9 (AD+) mice. (A) Description of the genetic composition for the 3 groups of bone marrow (BM) donor mice at the GFP, APPSWE/PS1ΔE9 (AD+), and ACE loci: GFP−AD+ACEWT, GFP+AD−ACEWT, or GFP+AD−ACE10. In the ACE10 mouse models, ACE expression is controlled by the c-fms (CD115) promoter that substituted the endogenous ACE promoter. This results in the over expression of ACE in monocytes and macrophages (Mo/MΦ). (B) BM transplantation experiments: 2-month-old double transgenic AD+ recipient mice underwent irradiation with head shielding to prevent brain irradiation and inflammation. Their BM was then reconstituted by an intravenous injection of 5 million BM cells from one of the three types of donors. This BM transplantation generated BMAD+ , BMWT, and BMACE10 chimeric AD+ mice. These mice underwent retinal imaging at the age of 7 months, followed by perfusion and harvest of eyes and brains for analysis. (C) A representative live fluorescence image of a BM-chimeric AD+ mouse retina, demonstrating the feasibility to noninvasively detect in vivo infiltrating GFP+ Mo/MΦ in the retina. [(D), left] Fluorescence micrograph of a BMACE10::AD+ chimeric mouse retina (previously in vivo imaged) showing the homing of GFP+/CD45hi ACE10 Mo/MΦ to the site of retinal 4G8+-Aβ deposit. Scale bar = 5 μm. [(D), right] Infiltrating Mo/MΦ (GFP+/CD45hi; arrows) at the 6E10+-Aβ plaque site are also detected in the BMWT::AD+ chimeric mouse brain. Scale bar = 20 μm. (E) Quantitative flow cytometry analysis of cerebral infiltrating GFP+-Mo/MΦ in BMACE10 versus BMWT chimeric AD+ mice. (F) Micrographs of curcumin+-Aβ plaques (yellow) or GFAP+ astrocytes (pink) in the cortices of BMWT versus BMACE10 AD+ chimeric mice. Scale bar = 50 μm. (G) Quantitative immunohistochemical (IHC) analysis of 6E10+-Aβ plaque area in the cortex of BMACE10 versus BMAD+ AD+-chimeric mice. (H) Quantitative IHC analysis of cortical GFAP+ astrocytosis area in AD+-chimeric mice. (I) Representative fluorescent micrographs of cortical brain regions stained against IGF-1 (red) combined with myeloid cell markers, IBA1 (white) and CD45 (green), and nuclei (DAPI, blue) in BMWT versus BMACE10 AD+-chimeric mice. Scale bars = 10 μm. Brain-infiltrating CD45hi IBA1+ ACE10-versus WT-Mo/MΦ highly expressed IGF-1 in AD+-chimeric mice. (J). Quantitative IHC analysis of % IGF-1+ area colocalized with Mo/MΦ in BMWT versus BMACE10 AD+-chimeric mice. (K) Quantitative flow cytometry analysis of TNFα expression levels in infiltrating ACE10-versus WT-MΦ (GFP+ CD11b+ CD45hi Ly6Cint-hi F4/80hi) in chimeric AD+ mice. (L) An additional study involved adoptive transfer of 5-6 million ACE10-or WT-CD115+ monocytes (MoBM) from young donor mice into the peripheral blood of 8-month-old AD+ mice. These inflammatory monocytes were isolated from the BM of GFP+ donor mice and enriched in the tube using the CD115-positive MACS column sorting procedure. ACE10- (MoACE10) or WT- (MoWT) BM were then injected into the tail vein of recipient AD+ mice. At the age of 11 months, mice underwent behavioral testing. (M) Barnes maze cognitive test: average errors count during the reversal phase, days 8 and 9. Statistics: (left) two-way ANOVA and Bonferroni’s post-test; (right) Day 9 memory test by one-way ANOVA and Bonferroni’s post test. (N) Severity of vascular Aβ deposits is defined as CAA score assessed with thioflavin-S (Thio-S+) staining in AD+ mice brain. (O) Quantitative IHC analysis of hippocampal pre-(VGluT1+) and post-(PSD95+) synaptic areas in MoACE10-treated mice compared to age- and gender-matched PBS-injected control AD+ and naïve WT mice. Illustration in panels A, B and L were created with Biorender.com, as well as images and graphs were used as original or modified from (Koronyo-Hamaoui et al., 2020) by permission of Oxford University Press.
FIGURE 1 Neuroprotection by ACE-overexpressing monocytes and macrophages in APPSWE/PS1ΔE9 (AD+) mice. (A) Description of the genetic composition for the 3 groups of bone marrow (BM) donor mice at the GFP, APPSWE/PS1ΔE9 (AD+), and ACE loci: GFP−AD+ACEWT, GFP+AD−ACEWT, or GFP+AD−ACE10. In the ACE10 mouse models, ACE expression is controlled by the c-fms (CD115) promoter that substituted the endogenous ACE promoter. This results in the over expression of ACE in monocytes and macrophages (Mo/MΦ). (B) BM transplantation experiments: 2-month-old double transgenic AD+ recipient mice underwent irradiation with head shielding to prevent brain irradiation and inflammation. Their BM was then reconstituted by an intravenous injection of 5 million BM cells from one of the three types of donors. This BM transplantation generated BMAD+ , BMWT, and BMACE10 chimeric AD+ mice. These mice underwent retinal imaging at the age of 7 months, followed by perfusion and harvest of eyes and brains for analysis. (C) A representative live fluorescence image of a BM-chimeric AD+ mouse retina, demonstrating the feasibility to noninvasively detect in vivo infiltrating GFP+ Mo/MΦ in the retina. [(D), left] Fluorescence micrograph of a BMACE10::AD+ chimeric mouse retina (previously in vivo imaged) showing the homing of GFP+/CD45hi ACE10 Mo/MΦ to the site of retinal 4G8+-Aβ deposit. Scale bar = 5 μm. [(D), right] Infiltrating Mo/MΦ (GFP+/CD45hi; arrows) at the 6E10+-Aβ plaque site are also detected in the BMWT::AD+ chimeric mouse brain. Scale bar = 20 μm. (E) Quantitative flow cytometry analysis of cerebral infiltrating GFP+-Mo/MΦ in BMACE10 versus BMWT chimeric AD+ mice. (F) Micrographs of curcumin+-Aβ plaques (yellow) or GFAP+ astrocytes (pink) in the cortices of BMWT versus BMACE10 AD+ chimeric mice. Scale bar = 50 μm. (G) Quantitative immunohistochemical (IHC) analysis of 6E10+-Aβ plaque area in the cortex of BMACE10 versus BMAD+ AD+-chimeric mice. (H) Quantitative IHC analysis of cortical GFAP+ astrocytosis area in AD+-chimeric mice. (I) Representative fluorescent micrographs of cortical brain regions stained against IGF-1 (red) combined with myeloid cell markers, IBA1 (white) and CD45 (green), and nuclei (DAPI, blue) in BMWT versus BMACE10 AD+-chimeric mice. Scale bars = 10 μm. Brain-infiltrating CD45hi IBA1+ ACE10-versus WT-Mo/MΦ highly expressed IGF-1 in AD+-chimeric mice. (J). Quantitative IHC analysis of % IGF-1+ area colocalized with Mo/MΦ in BMWT versus BMACE10 AD+-chimeric mice. (K) Quantitative flow cytometry analysis of TNFα expression levels in infiltrating ACE10-versus WT-MΦ (GFP+ CD11b+ CD45hi Ly6Cint-hi F4/80hi) in chimeric AD+ mice. (L) An additional study involved adoptive transfer of 5-6 million ACE10-or WT-CD115+ monocytes (MoBM) from young donor mice into the peripheral blood of 8-month-old AD+ mice. These inflammatory monocytes were isolated from the BM of GFP+ donor mice and enriched in the tube using the CD115-positive MACS column sorting procedure. ACE10- (MoACE10) or WT- (MoWT) BM were then injected into the tail vein of recipient AD+ mice. At the age of 11 months, mice underwent behavioral testing. (M) Barnes maze cognitive test: average errors count during the reversal phase, days 8 and 9. Statistics: (left) two-way ANOVA and Bonferroni’s post-test; (right) Day 9 memory test by one-way ANOVA and Bonferroni’s post test. (N) Severity of vascular Aβ deposits is defined as CAA score assessed with thioflavin-S (Thio-S+) staining in AD+ mice brain. (O) Quantitative IHC analysis of hippocampal pre-(VGluT1+) and post-(PSD95+) synaptic areas in MoACE10-treated mice compared to age- and gender-matched PBS-injected control AD+ and naïve WT mice. Illustration in panels A, B and L were created with Biorender.com, as well as images and graphs were used as original or modified from (Koronyo-Hamaoui et al., 2020) by permission of Oxford University Press.CC BY · PubMed Central
FIGURE 2 Enhanced clearance of Aβ42 assemblies by ACE-overexpressing macrophages. (A) In vitro experimental procedure: BM was isolated from young WT and ACE10 mice (8–12 weeks old) and cultured for 6 days with macrophage colony stimulating factor (MCSF)-enriched media, generating primary macrophage cultures (MΦWT and MΦACE10, respectively). On Day 7, MΦ were either unstimulated (Un) or stimulated by one of the 3 Aβ42 forms: fibrils (fAβ42), prion rod-like structures (pAβ42), or cross-linked oligomers (oAβ42). MΦACE10 were analyzed and compared to control MΦWT for cell surface Aβ42 binding and receptor expression as well as uptake of Aβ42 species at incremental time points from 5 to 15 min (incubated at 37°C). Additional experimental groups were pretreated at day 6 with the ACE inhibitor lisinopril, blocking its two catalytic domains. (B) Representative fluorescence micrograph of MΦWT and MΦACE10 cells that were incubated for 5 min with 250 nM fibril Aβ42 and later immunolabelled for Scara1 (red), human Aβ (6E10, green; white arrows indicate intracellular Aβ within vesicles in these phagocytic cells), and nuclei (DAPI, blue). (C) Quantitative immunocytochemistry (ICC) analysis of 6E10+ IR area (μm2/cell #) following intracellular uptake of the 3 Aβ42 species (fAβ42, pAβ42, or oAβ42) by MΦACE10 versus MΦWT in a period of 15 min. (D) Quantitative ICC of cell surface CD36 scavenger receptor expression (μm2/cell #) in MΦACE10 versus MΦWT following 15-min exposed to the three types of Aβ42 species. (E) Quantitative analysis of colocalized 6E10+ within EEA1+ endosomes in MΦWT versus MΦACE10 following exposure to the three types of Aβ42 species. (F) Representative flow cytometry peak analysis in % MFI of HiLyte Fluor 647-labelled fAβ42 uptake by MΦACE10 at the 0-, 5- and 15-min time points. (G) MFI analysis of HiLyte Fluor 647-labelled fAβ42 uptake by MΦACE10 at the 0-, 5- and 15-min time points, with and without lisinopril pretreatment. (H) MSD biochemical assay determined TNFα levels in MΦWT versus MΦACE10, either unstimulated (−) or stimulated (+) with Aβ42 fibrils [100 nM] for 24 h. MFI, Median Fluorescence Intensity. Illustration in panel A created with Biorender.com and other panels modified or adapted from (Koronyo-Hamaoui et al., 2020) by permission of Oxford University Press.
FIGURE 2 Enhanced clearance of Aβ42 assemblies by ACE-overexpressing macrophages. (A) In vitro experimental procedure: BM was isolated from young WT and ACE10 mice (8–12 weeks old) and cultured for 6 days with macrophage colony stimulating factor (MCSF)-enriched media, generating primary macrophage cultures (MΦWT and MΦACE10, respectively). On Day 7, MΦ were either unstimulated (Un) or stimulated by one of the 3 Aβ42 forms: fibrils (fAβ42), prion rod-like structures (pAβ42), or cross-linked oligomers (oAβ42). MΦACE10 were analyzed and compared to control MΦWT for cell surface Aβ42 binding and receptor expression as well as uptake of Aβ42 species at incremental time points from 5 to 15 min (incubated at 37°C). Additional experimental groups were pretreated at day 6 with the ACE inhibitor lisinopril, blocking its two catalytic domains. (B) Representative fluorescence micrograph of MΦWT and MΦACE10 cells that were incubated for 5 min with 250 nM fibril Aβ42 and later immunolabelled for Scara1 (red), human Aβ (6E10, green; white arrows indicate intracellular Aβ within vesicles in these phagocytic cells), and nuclei (DAPI, blue). (C) Quantitative immunocytochemistry (ICC) analysis of 6E10+ IR area (μm2/cell #) following intracellular uptake of the 3 Aβ42 species (fAβ42, pAβ42, or oAβ42) by MΦACE10 versus MΦWT in a period of 15 min. (D) Quantitative ICC of cell surface CD36 scavenger receptor expression (μm2/cell #) in MΦACE10 versus MΦWT following 15-min exposed to the three types of Aβ42 species. (E) Quantitative analysis of colocalized 6E10+ within EEA1+ endosomes in MΦWT versus MΦACE10 following exposure to the three types of Aβ42 species. (F) Representative flow cytometry peak analysis in % MFI of HiLyte Fluor 647-labelled fAβ42 uptake by MΦACE10 at the 0-, 5- and 15-min time points. (G) MFI analysis of HiLyte Fluor 647-labelled fAβ42 uptake by MΦACE10 at the 0-, 5- and 15-min time points, with and without lisinopril pretreatment. (H) MSD biochemical assay determined TNFα levels in MΦWT versus MΦACE10, either unstimulated (−) or stimulated (+) with Aβ42 fibrils [100 nM] for 24 h. MFI, Median Fluorescence Intensity. Illustration in panel A created with Biorender.com and other panels modified or adapted from (Koronyo-Hamaoui et al., 2020) by permission of Oxford University Press.CC BY · PubMed Central
FIGURE 3 Proposed mechanism for neuroprotective role of ACE overexpression in monocytes in AD. (A) ACE overexpression under the activation of the c-fms promotor in CD115+ monocytes is named ACE10 model. CD115+ ACE10-monocytes exhibit a neuroprotective phenotype with lower expression of pro-inflammatory mediators such as iNOS and TNFα and increased expression of the neurotrophic factor IGF-1, Aβ-degrading enzymes (ACE, MMP-9), and surface scavenger receptors as CD36 and Scara-1 that facilitate phagocytosis of Aβ. (B) CD115+ ACE10-monocytes are recruited in larger numbers than WT monocytes to AD-like brains and retinas, resulting in neuro-immunomodulation. The ACE10 monocyte-derived macrophages aggregate at areas of amyloid plaque deposition and facilitate the clearance of Aβ oligomers and plaques. This is concomitant with reduced microgliosis and astrogliosis. Notably, in the ACE10 versus WT macrophages, there is increased presence of Aβ assemblies within EEA1 endosomes, suggesting enhanced intracellular lysosomal Aβ degradation machinery in ACE10 macrophages. (C) Murine models of AD treated with ACE10 monocytes show reduced AD-related pathology, preservation of excitatory synapses, and (D) improved cognitive functions. Created with Biorender.com.
FIGURE 3 Proposed mechanism for neuroprotective role of ACE overexpression in monocytes in AD. (A) ACE overexpression under the activation of the c-fms promotor in CD115+ monocytes is named ACE10 model. CD115+ ACE10-monocytes exhibit a neuroprotective phenotype with lower expression of pro-inflammatory mediators such as iNOS and TNFα and increased expression of the neurotrophic factor IGF-1, Aβ-degrading enzymes (ACE, MMP-9), and surface scavenger receptors as CD36 and Scara-1 that facilitate phagocytosis of Aβ. (B) CD115+ ACE10-monocytes are recruited in larger numbers than WT monocytes to AD-like brains and retinas, resulting in neuro-immunomodulation. The ACE10 monocyte-derived macrophages aggregate at areas of amyloid plaque deposition and facilitate the clearance of Aβ oligomers and plaques. This is concomitant with reduced microgliosis and astrogliosis. Notably, in the ACE10 versus WT macrophages, there is increased presence of Aβ assemblies within EEA1 endosomes, suggesting enhanced intracellular lysosomal Aβ degradation machinery in ACE10 macrophages. (C) Murine models of AD treated with ACE10 monocytes show reduced AD-related pathology, preservation of excitatory synapses, and (D) improved cognitive functions. Created with Biorender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 78

  1. Arjunan, 2023, Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): A promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome, Cell. Biosci., 13, 16, 10.1186/s13578-023-00966-z · DOI
  2. Baudin, 2002, New aspects on angiotensin-converting enzyme: From gene to disease, Clin. Chem. Lab. Med., 40, 256, 10.1515/CCLM.2002.042 · DOI
  3. Bernstein, 2018, Angiotensin-converting enzyme in innate and adaptive immunity, Nat. Rev. Nephrol., 14, 325, 10.1038/nrneph.2018.15 · DOI
  4. Bernstein, 2014, Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline, J. Clin. Invest., 124, 1000, 10.1172/JCI66541 · DOI
  5. Bernstein, 2013, A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme, Pharmacol. Rev., 65, 1, 10.1124/pr.112.006809 · DOI
  6. Bertram, 2007, Systematic meta-analyses of alzheimer disease genetic association studies: The AlzGene database, Nat. Genet., 39, 17, 10.1038/ng1934 · DOI · Paper page
  7. Brice, 1995, Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD, Chest, 107, 706, 10.1378/chest.107.3.706 · DOI
  8. Brody, 2018, Synaptotoxic signaling by amyloid beta oligomers in Alzheimer’s disease through prion protein and mGluR5, Adv Pharmacol., 82, 293, 10.1016/bs.apha.2017.09.007 · DOI
  9. Butovsky, 2006, Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1, Proc. Natl. Acad. Sci. U. S. A., 103, 11784, 10.1073/pnas.0604681103 · DOI · Paper page
  10. Butovsky, 2007, Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model, Eur. J. Neurosci., 26, 413, 10.1111/j.1460-9568.2007.05652.x · DOI
  11. Cao, 2023, Macrophage angiotensin-converting enzyme (ACE) reduces atherosclerosis by increasing PPARα and fundamentally changing lipid metabolism, Cardiovasc Res, 10.1093/cvr/cvad082 · DOI
  12. Cao, Role of angiotensin-converting enzyme in myeloid cell immune responses, Cell. Mol. Biol. Lett., 25, 31, 10.1186/s11658-020-00225-w · DOI
  13. Cao, ACE overexpression in myeloid cells increases oxidative metabolism and cellular ATP, J. Biol. Chem., 295, 1369, 10.1074/jbc.RA119.011244 · DOI
  14. Cenini, 2010, Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways, Amino Acids, 38, 1101, 10.1007/s00726-009-0319-7 · DOI
  15. Chang, 2017, Tumor necrosis factor alpha Inhibition for Alzheimer's Disease, J. Cent. Nerv. Syst. Dis., 9, 9278, 10.1177/1179573517709278 · DOI · Paper page
  16. Charidimou, 2017, Emerging concepts in sporadic cerebral amyloid angiopathy, Brain, 140, 1829, 10.1093/brain/awx047 · DOI · Paper page
  17. Cunningham, 2013, Microglia and neurodegeneration: The role of systemic inflammation, Glia, 61, 71, 10.1002/glia.22350 · DOI · Paper page
  18. Deane, 2009, Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease, CNS Neurol. Disord. Drug Targets, 8, 16, 10.2174/187152709787601867 · DOI
  19. Diet, 1996, Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease, Circulation, 94, 2756, 10.1161/01.cir.94.11.2756 · DOI
  20. Doustar, 2020, Parallels between retinal and brain pathology and response to immunotherapy in old, late-stage Alzheimer's disease mouse models, Aging Cell., 19, 13246, 10.1111/acel.13246 · DOI
  21. Dvir-Szternfeld, 2022, Alzheimer's disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis, Nat. Aging, 2, 60, 10.1038/s43587-021-00149-w · DOI
  22. George, 2017, The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons, Brain, 140, 2012, 10.1093/brain/awx132 · DOI
  23. Grober, 1999, Memory and mental status correlates of modified Braak staging, Neurobiol. Aging, 20, 573, 10.1016/s0197-4580(99)00063-9 · DOI
  24. Han, 2017, Amyloid beta-42 induces neuronal apoptosis by targeting mitochondria, Mol. Med. Rep., 16, 4521, 10.3892/mmr.2017.7203 · DOI
  25. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  26. He, 2006, ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease, Neurology, 67, 1309, 10.1212/01.wnl.0000238102.04582.ec · DOI
  27. Hemming, 2005, Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor, J. Biol. Chem., 280, 37644, 10.1074/jbc.M508460200 · DOI
  28. Jochemsen, 2014, The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease, Alzheimers Res. Ther., 6, 27, 10.1186/alzrt257 · DOI · Paper page
  29. Kanemitsu, 2003, Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form, Neurosci. Lett., 350, 113, 10.1016/s0304-3940(03)00898-x · DOI
  30. Kehoe, 2019, Cerebrospinal fluid changes in the renin-angiotensin system in Alzheimer's disease, J. Alzheimers Dis., 72, 525, 10.3233/JAD-190721 · DOI
  31. Kehoe, 2009, Angiotensins in Alzheimer's disease - friend or foe?, Trends Neurosci., 32, 619, 10.1016/j.tins.2009.07.006 · DOI
  32. Keren-Shaul, 2017, A unique microglia type associated with restricting development of Alzheimer's disease, Cell., 169, 1276, 10.1016/j.cell.2017.05.018 · DOI · Paper page
  33. Koronyo, 2017, Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease, JCI Insight, 2, 93621, 10.1172/jci.insight.93621 · DOI
  34. Koronyo, 2023, Retinal pathological features and proteome signatures of Alzheimer's disease, Acta Neuropathol., 145, 409, 10.1007/s00401-023-02548-2 · DOI
  35. Koronyo-Hamaoui, 2009, Attenuation of AD-like neuropathology by harnessing peripheral immune cells: Local elevation of IL-10 and MMP-9, J. Neurochem., 111, 1409, 10.1111/j.1471-4159.2009.06402.x · DOI
  36. Koronyo-Hamaoui, 2011, Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model, Neuroimage, 54, S204, 10.1016/j.neuroimage.2010.06.020 · DOI · Paper page
  37. Koronyo-Hamaoui, 2014, ACE overexpression in myelomonocytic cells: effect on a mouse model of Alzheimer’s disease, Curr. Hypertens. Rep., 16, 444, 10.1007/s11906-014-0444-x · DOI
  38. Koronyo-Hamaoui, 2020, Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease, Brain, 143, 336, 10.1093/brain/awz364 · DOI
  39. Krasemann, 2017, The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases, Immunity, 47, 566, 10.1016/j.immuni.2017.08.008 · DOI · Paper page
  40. La Morgia, 2016, Melanopsin retinal ganglion cell loss in Alzheimer disease, Ann. Neurol., 79, 90, 10.1002/ana.24548 · DOI
  41. Lebson, 2010, Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice, J. Neurosci., 30, 9651, 10.1523/JNEUROSCI.0329-10.2010 · DOI
  42. Li, 2020, Activated bone marrow-derived macrophages eradicate alzheimer's-related Aβ42 oligomers and protect synapses, Front. Immunol., 11, 49, 10.3389/fimmu.2020.00049 · DOI
  43. Lieberman, 1975, Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis, Am. J. Med., 59, 365, 10.1016/0002-9343(75)90395-2 · DOI
  44. Marioni, 2019, Correction: GWAS on family history of Alzheimer's disease, Transl. Psychiatry, 9, 161, 10.1038/s41398-019-0498-2 · DOI
  45. Marques, 2009, Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system, J. Alzheimers Dis., 16, 325, 10.3233/JAD-2009-0964 · DOI
  46. Mateos, 2011, Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease, J. Alzheimers Dis., 24, 669, 10.3233/JAD-2011-101512 · DOI
  47. Meng, 2006, Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community, Am. J. Hum. Genet., 78, 871, 10.1086/503687 · DOI · Paper page
  48. Miners, 2008, Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy, Neuropathol. Appl. Neurobiol., 34, 181, 10.1111/j.1365-2990.2007.00885.x · DOI
  49. Miners, 2009, Angiotensin-converting enzyme levels and activity in Alzheimer's disease: Differences in brain and CSF ACE and association with ACE1 genotypes, Am. J. Transl. Res., 1, 163
  50. Morgan, 2005, Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for alzheimer therapeutics, J. Neuropathol. Exp. Neurol., 64, 743, 10.1097/01.jnen.0000178444.33972.e0 · DOI
  51. Mukherjee, 2000, Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques, J. Neurosci., 20, 8745, 10.1523/JNEUROSCI.20-23-08745.2000 · DOI
  52. Ohishi, 1997, Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans, J. Hypertens., 15, 1295, 10.1097/00004872-199715110-00014 · DOI
  53. Okwan-Duodu, 2010, Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to Listeria and methicillin-resistant Staphylococcus aureus, J. Biol. Chem., 285, 39051, 10.1074/jbc.M110.163782 · DOI
  54. Pimentel-Coelho, 2012, The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease, Eur. J. Neurosci., 35, 1917, 10.1111/j.1460-9568.2012.08126.x · DOI
  55. Prinz, 2017, The role of peripheral immune cells in the CNS in steady state and disease, Nat. Neurosci., 20, 136, 10.1038/nn.4475 · DOI · Paper page
  56. Rentsendorj, 2018, A novel role for osteopontin in macrophage-mediated amyloid-beta clearance in Alzheimer's models, Brain Behav. Immun., 67, 163, 10.1016/j.bbi.2017.08.019 · DOI
  57. Rossi, 2021, Common peripheral immunity mechanisms in multiple sclerosis and Alzheimer's disease, Front. Immunol., 12, 639369, 10.3389/fimmu.2021.639369 · DOI
  58. Selkoe, 2001, Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein, J. Alzheimers Dis., 3, 75, 10.3233/jad-2001-3111 · DOI · Paper page
  59. Selkoe, 2008, Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior, Behav. Brain Res., 192, 106, 10.1016/j.bbr.2008.02.016 · DOI · Paper page
  60. Shankar, 2007, Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway, J. Neurosci., 27, 2866, 10.1523/JNEUROSCI.4970-06.2007 · DOI · Paper page
  61. Shankar, 2008, Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory, Nat. Med., 14, 837, 10.1038/nm1782 · DOI · Paper page
  62. Shankar, 2009, Alzheimer's disease: Synaptic dysfunction and abeta, Mol. Neurodegener., 4, 48, 10.1186/1750-1326-4-48 · DOI · Paper page
  63. Shen, 2007, Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma, Am. J. Pathol., 170, 2122, 10.2353/ajpath.2007.061205 · DOI
  64. Shi, 2020, Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina, Acta Neuropathol., 139, 813, 10.1007/s00401-020-02134-w · DOI · Paper page
  65. Simard, 2006, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease, Neuron, 49, 489, 10.1016/j.neuron.2006.01.022 · DOI · Paper page
  66. Tu, 2014, Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease, Mol. Neurodegener., 9, 48, 10.1186/1750-1326-9-48 · DOI
  67. Umeda, 2015, Intracellular amyloid beta oligomers impair organelle transport and induce dendritic spine loss in primary neurons, Acta Neuropathol. Commun., 3, 51, 10.1186/s40478-015-0230-2 · DOI
  68. Walsh, 2002, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo, Nature, 416, 535, 10.1038/416535a · DOI · Paper page
  69. Wei, 1991, The two homologous domains of human angiotensin I-converting enzyme are both catalytically active, J. Biol. Chem., 266, 9002, 10.1016/s0021-9258(18)31543-6 · DOI
  70. Williams, 1983, Granulomatous inflammation-a review, J. Clin. Pathol., 36, 723, 10.1136/jcp.36.7.723 · DOI
  71. Xin, 2021, Angiotensin-converting enzyme polymorphisms AND Alzheimer's disease susceptibility: An updated meta-analysis, PLoS One, 16, 0260498, 10.1371/journal.pone.0260498 · DOI
  72. Xu, 2016, Microglia-mediated inflammation and neurodegenerative disease, Mol. Neurobiol., 53, 6709, 10.1007/s12035-015-9593-4 · DOI
  73. Yan, 2022, Peripheral monocyte-derived cells counter amyloid plaque pathogenesis in a mouse model of Alzheimer's disease, J. Clin. Invest., 132, 152565, 10.1172/JCI152565 · DOI · Paper page
  74. Yin, 2006, Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism, J. Neurosci., 26, 10939, 10.1523/JNEUROSCI.2085-06.2006 · DOI · Paper page
  75. Yu, 2019, Association of cortical beta-amyloid protein in the absence of insoluble deposits with alzheimer disease, JAMA Neurol., 76, 818, 10.1001/jamaneurol.2019.0834 · DOI
  76. Zhang, 2013, Systemic immune system alterations in early stages of Alzheimer's disease, J. Neuroimmunol., 256, 38, 10.1016/j.jneuroim.2013.01.002 · DOI
  77. Zou, 2007, Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition, J. Neurosci., 27, 8628, 10.1523/JNEUROSCI.1549-07.2007 · DOI
  78. Zuroff, 2017, Clearance of cerebral Aβ in Alzheimer's disease: Reassessing the role of microglia and monocytes, Cell. Mol. Life Sci., 74, 2167, 10.1007/s00018-017-2463-7 · DOI

Cited by

Sorted by citations

Metadata

Authors
Danziger, R., Fuchs, D.-T., Koronyo, Y., Rentsendorj, A., Sheyn, J., Hayden, E. Y., Teplow, D. B., Black, K. L., Fuchs, S., Bernstein, K. E., & Koronyo-Hamaoui, M.
Venue
Frontiers in Physiology
Publisher
Frontiers Media SA
Published
2023-06-23
Volume
14
ISSN
1664-042X
DOI
10.3389/fphys.2023.1179315
PMC
PMC10326285
Cited by
16
References
15
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • National Institute on Aging (R01 AG042195 R01 AG056478 R01 AG075998 R01 AG055865)
  • BrightFocus Foundation (A2013328S00)
  • Coins for Alzheimer’s Research Trust (CART fund)
  • Clinical and Translational Science Institute, University of California, Los Angeles (UL1TR000124)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review